+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07100106

Evaluating GDC-4198 Alone and With Giredestrant Compared to Abemaciclib Plus Giredestrant in Locally Advanced or Metastatic ER, HER2- Breast Cancer

Led by Genentech, Inc. · Updated on 2026-10-26

285

Participants Needed

77

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of GDC-4198 alone and combined with giredestrant compared to abemaciclib plus giredestrant in people with locally advanced or metastatic estrogen receptor-positive ER, HER2-negative breast cancer. This study includes two parts Phase Ib to assess safety and how the body processes GDC-4198, and Phase II to compare the activity and safety of the two treatment combinations. Participants benefiting from GDC-4198 in a previous study may continue with this treatment. Participants receive GDC-4198 by mouth either alone or with giredestrant daily in 28-day cycles until unacceptable side effects, disease progression, or loss of benefit. Different dosing levels of GDC-4198 combined with giredestrant are studied, and others receive abemaciclib with giredestrant. Those from the earlier study continuing treatment keep their current dose of GDC-4198. During the study, participants will be regularly monitored for side effects and treatment impact, including disease progression and response rates. Researchers will track adverse events, dose-limiting toxicities, progression-free survival, and overall survival for up to 36 months. Assessments include safety evaluations, pharmacokinetics of GDC-4198, and measuring clinical benefit throughout the trial period.

CONDITIONS

Brief Title

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Research Team

R

Reference Study ID Number: GO46021 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here